EI Evommune, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Evommune, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €544.7m. The latest transaction was reported on 10 July 2026 (Acquisition). Among the most active insiders: Carver Kyle. The full history is free.
€636,992
5 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Evommune, Inc. Buy (bullish), based on 7 analysts. Average price target: US$27.57.
Buys €142,626 €636,992 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 July 2026
All Executives36 Thresholds0 Prospectus0 Other0
Declarations 36 total
▲ Chief Financial Officer · Executives · 8 Jul 2026
1,000 shares @ US$13.26 0.0029% mcap 1.9% of flow Common Stock SEC:0001757072-26-000007:0
Canonical exit: 6 Oct 2026 (T+90) ▲ Director · Executives · 7 Jul 2026
10,000 shares @ US$13.30 0.030% mcap 100.0% of flow Common Stock SEC:0001290976-26-000004:0
Canonical exit: 5 Oct 2026 (T+90) ◇ Chief of Dev. Operations · Executives · 22 Jun 2026
3,839 shares Common Stock SEC:0002091053-26-000005:0
◇ Chief of Dev. Operations · Executives · 22 Jun 2026
16,161 shares Common Stock SEC:0002091053-26-000005:1
▼ Chief of Dev. Operations · Executives · 22 Jun 2026
20,000 shares Common Stock SEC:0002091053-26-000005:2
▼ President & CEO · Executives · 22 Jun 2026
7,438 shares Common Stock SEC:0001620548-26-000007:0
◇ Chief Scientific Officer · Executives · 22 Jun 2026
1,488 shares Common Stock SEC:0002092017-26-000007:0
▼ Chief Scientific Officer · Executives · 22 Jun 2026
1,488 shares Common Stock SEC:0002092017-26-000007:1
● Officer · Executives · 22 Jun 2026
20,000 shares @ US$21.36 0.094% mcap 100.0% of flow Common SEC144:0001950047-26-006381
● Director · Executives · 2 Jun 2026
9,258 shares @ US$22.17 0.046% mcap 100.0% of flow Common SEC144:0001950047-26-005513
◇ Chief Financial Officer · Executives · 28 May 2026
15,000 shares @ US$2.99 9.8% of flow Common Stock SEC:0001757072-26-000005:0
▼ Chief Financial Officer · Executives · 28 May 2026
18,175 shares @ US$22.84 90.2% of flow Common Stock SEC:0001757072-26-000005:1
◇ Chief Business & Legal Officer · Executives · 28 May 2026
14,223 shares @ US$1.71 7.0% of flow Common Stock SEC:0001742496-26-000005:0
▼ Chief Business & Legal Officer · Executives · 28 May 2026
14,223 shares @ US$22.83 93.0% of flow Common Stock SEC:0001742496-26-000005:1
◆ Director · Executives · 17 Feb 2026
358,680 shares @ US$27.88 100.0% of flow Common Stock SEC:0001193125-26-059500:0
◆ Director · Executives · 17 Feb 2026
358,680 shares @ US$27.88 100.0% of flow Common Stock SEC:0002094941-26-000002:0
◆ Director · Executives · 17 Feb 2026
35,868 shares @ US$27.88 100.0% of flow Common Stock SEC:0001231919-26-000164:0
▲ Director · Executives · 19 Dec 2025
1,000 shares @ US$17.35 100.0% of flow Common Stock SEC:0001012975-25-000937:0
Canonical exit: 19 Mar 2026 (T+90) ● Chief Scientific Officer · Executives · 9 Dec 2025
7,513 shares @ US$17.84 100.0% of flow Common Stock SEC:0002092017-25-000009:0
● EVP, Operations · Executives · 9 Dec 2025
5,074 shares @ US$17.84 100.0% of flow Common Stock SEC:0002091053-25-000009:0
● Chief Financial Officer · Executives · 9 Dec 2025
13,290 shares @ US$17.84 34.0% of flow Common Stock SEC:0001757072-25-000010:0
● Chief Business & Legal Officer · Executives · 9 Dec 2025
13,624 shares @ US$17.84 41.0% of flow Common Stock SEC:0001742496-25-000012:0
● Chief Medical Officer · Executives · 9 Dec 2025
1,478 shares @ US$17.84 100.0% of flow Common Stock SEC:0001678620-25-000011:0
● President & CEO · Executives · 9 Dec 2025
28,138 shares @ US$17.84 100.0% of flow Common Stock SEC:0001620548-25-000011:0
● Director · Executives · 7 Nov 2025
6,056 shares Common Stock SEC:0001347383-25-000009:0
25 of 36 declarations
Load more (11 remaining) 关于 Evommune, Inc. Evommune, Inc. 是一家在 XNAS 市场上市的公司，专注于开发医疗保健领域的创新解决方案。该公司致力于自身免疫疾病治疗方法的研究和商业化。